Arcutis Biotherapeutics, Inc. ARQT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | -$44.32M+52.5% | -$93.27M+28.1% | -$129.72M+7.4% | ||
| $41.28M+2.3% | $40.36M+1.7% | $39.7M+0.6% | $39.44M-4.9% | $41.48M-0.6% | ||
| —— | —— | —— | —— | -$110.94M+1.1% | ||
| —— | —— | —— | $829K+10.4% | $751K+425% | ||
| -$53.34M-76.3% | -$30.25M-178% | $38.8M-73.9% | $148.83M+115% | $69.27M+140% | ||
| —— | $0-100% | $25M-50.0% | $50M-33.3% | $75M-25.0% | ||
| $7.65M+9.6% | $6.97M— | —— | —— | —— | ||
| -$18.65M+35.1% | -$28.74M+67.4% | -$88.04M-644% | -$11.84M+91.4% | -$136.99M-689% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Arcutis Biotherapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.